SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · MO

Altria Reports 2026 Third-Quarter and Nine-Months Results

Altria Group, Inc. · Filed · SEC Form 8-K, Item 2.02

Altria company page Original on SEC.gov ↗

Revenue $6.1 billion +1% vs a year ago
EPS $1.51 not detected
Guidance raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue rose 1% year on year to $6.1 billion, and EPS was $1.51. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$6.1 billion +1% vs a year ago

…Net revenues increased 1.0% to $6.1 billion, primarily driven by higher net revenues in the smokeable produ…
EPS

$1.51

…Reported diluted EPS $1.51 7.1% $4.18 21.2%.…
Guidance

Guidance raised

…2026 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Raises 2026 Full-Year Earnings Guidance. | (NYSE: MO) today reports our 2026 third-quarter and nine-months business results and raises our guidance for 2026 full-year adjusted diluted earning…

Read the original press release on SEC.gov ↗ Filing index ↗

Our research on MO

Company page →

Altria (MO): The Forensic Case That Death-Spiral Math Is Running In Reverse

Altria has re-rated 27% to ~$72, yet still trades at 13x against a 19x historical average while consensus prices three demonstrably wrong calls: a "volume cliff" offset by relentless pricing power, a smoke-free option marked near zero after NJOY, and a ~$9B ABI stake buried by single-multiple math. Forensic case: BUY, $82 in 12 months, $95+ long-term.

· 12 min read

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.